8-K: Current report filing
Published on September 19, 2007
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
___________________
FORM
8-K
___________________
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date
of
Report: September 14, 2007
(Date
of earliest event reported)
NOVELOS
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
333-119366
|
04-3321804
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
Number)
|
One
Gateway Center, Suite 504
Newton,
MA 02458
(Address
of principal executive offices)
(617)
244-1616
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers
On
September 14, 2007 the board of directors of Novelos Therapeutics, Inc. (the
“Company”) increased the number of directors to eight and elected Stephen A.
Hill, B.M. B.Ch., M.A., F.R.C.S., as chairman of the Company’s board of
directors. Upon his election, Dr. Hill received an option to purchase 150,000
shares of the Company’s common stock at an exercise price of $0.70 per share
which represents the closing price of the Company’s common stock on September
14, 2007 as reported on the Over the Counter Bulletin Board, vesting quarterly
over two years. Dr. Hill will also receive a $15,000 annual fee for his service
as chairman as well as quarterly director fees and compensation for meeting
attendance consistent with the Company’s practice for other independent
directors.
Item
9.01 Financial
Statements and Exhibits
| (d) | Exhibits |
|
10.1
|
Press
Release dated September 19, 2007
|
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| NOVELOS THERAPEUTICS, INC. | ||
| |
|
|
| Date: September 19, 2007 | By: | /s/ Harry S. Palmin |
|
Name: Harry S. Palmin |
||
| Title: President and Chief Executive Officer | ||
3
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
|
10.1
|
Press
Release dated September 19, 2007
|
|
4